GEP20207204B - Depot formulations - Google Patents

Depot formulations

Info

Publication number
GEP20207204B
GEP20207204B GEAP202014989A GEAP2020014989A GEP20207204B GE P20207204 B GEP20207204 B GE P20207204B GE AP202014989 A GEAP202014989 A GE AP202014989A GE AP2020014989 A GEAP2020014989 A GE AP2020014989A GE P20207204 B GEP20207204 B GE P20207204B
Authority
GE
Georgia
Prior art keywords
depot formulations
diluent
hvlcm
saib
articles
Prior art date
Application number
GEAP202014989A
Other languages
English (en)
Georgian (ka)
Inventor
Naoki Matsumoto
Komei Okabe
Kazuhito Yamada
Weiqi Lin
Huey-Ching Lin Su
Sreenivasu Mudumba
Wilma Tamraz
Original Assignee
Santen Pharmaceutical Co Ltd
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Durect Corp filed Critical Santen Pharmaceutical Co Ltd
Publication of GEAP202014989A publication Critical patent/GEAP202014989A/en
Publication of GEP20207204B publication Critical patent/GEP20207204B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/02—Monohydroxylic acyclic alcohols
    • C07C31/08—Ethanol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/12—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
GEAP202014989A 2016-06-30 2017-06-29 Depot formulations GEP20207204B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356613P 2016-06-30 2016-06-30
US201662440658P 2016-12-30 2016-12-30

Publications (2)

Publication Number Publication Date
GEAP202014989A GEAP202014989A (en) 2020-07-27
GEP20207204B true GEP20207204B (en) 2020-12-25

Family

ID=60786467

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202014989A GEP20207204B (en) 2016-06-30 2017-06-29 Depot formulations

Country Status (16)

Country Link
US (2) US10668011B2 (enExample)
EP (1) EP3478285A4 (enExample)
JP (2) JP7051721B2 (enExample)
KR (1) KR20190025635A (enExample)
CN (2) CN109310680B (enExample)
AU (2) AU2017290143A1 (enExample)
BR (1) BR112018077259A2 (enExample)
CA (1) CA2972296A1 (enExample)
GE (1) GEP20207204B (enExample)
IL (1) IL263714A (enExample)
MX (1) MX387477B (enExample)
PH (1) PH12018502615A1 (enExample)
SG (1) SG11201810618QA (enExample)
TW (1) TWI765898B (enExample)
UA (1) UA124768C2 (enExample)
WO (2) WO2018005777A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016148228A1 (ja) * 2015-03-18 2016-09-22 参天製薬株式会社 徐放性医薬組成物
JP7051721B2 (ja) 2016-06-30 2022-04-11 デュレクト コーポレーション デポー製剤
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
CN112423740A (zh) * 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法
EP3787611A4 (en) 2018-05-01 2022-03-09 Chibi, Inc. LIQUID DEPOT FOR NONINVASIVE DELAYED DELIVERY OF DRUGS TO THE EYE
CN113853196B (zh) * 2019-05-24 2024-04-12 皮埃蒙特动物健康公司 长效可注射调配物和其用途
CN113117049A (zh) * 2019-12-31 2021-07-16 齐鲁制药有限公司 一种索玛鲁肽原位凝胶制剂及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
ES2139646T3 (es) 1991-12-19 2000-02-16 Mitsui Chemicals Inc Acido polihidroxido carboxilico y su procedimiento de obtencion.
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
DK1006935T3 (da) 1995-06-07 2005-06-06 Durect Corp Styret afgivelsessystem med en væske med höj viskositet
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
AU2002242231B2 (en) 2001-02-23 2007-09-06 Genentech, Inc. Erodible polymers for injection
ATE419831T1 (de) 2002-07-31 2009-01-15 Alza Corp Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen
ES2494791T3 (es) 2002-09-18 2014-09-16 Trustees Of The University Of Pennsylvania Uso de rapamicina para el tratamiento o prevención de la degeneración macular asociada a la edad
AU2003295409B2 (en) 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
ES2553136T3 (es) 2002-12-13 2015-12-04 Durect Corporation Sistema de administración oral de fármacos que comprende materiales vehículos líquidos de alta viscosidad
AU2004219595A1 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
KR101492361B1 (ko) 2004-09-17 2015-02-11 듀렉트 코퍼레이션 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는 지속적인 국소 마취제 조성물
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1853259A1 (en) 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
JP2008533204A (ja) * 2005-03-21 2008-08-21 マクサイト， インコーポレイテッド 病気又は症状の治療のためのドラッグ送達システム
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
CN1973822A (zh) 2006-12-20 2007-06-06 山东蓝金生物工程有限公司 一种含雷帕霉素的抗癌组合物
US20100184659A1 (en) 2006-12-21 2010-07-22 Warren Jaworowicz Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents
AU2008254538B2 (en) 2007-05-18 2013-11-07 Durect Corporation Improved depot formulations
ES2507078T3 (es) 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
JP5737949B2 (ja) 2008-02-08 2015-06-17 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
CA2760932A1 (en) 2009-05-04 2010-11-11 Thierry Nivaggioli Mtor pathway inhibitors for treating ocular disorders
EA026964B1 (ru) 2010-11-24 2017-06-30 Дьюрект Корпорейшн Биоразлагаемая композиция для доставки лекарственного средства (варианты)
WO2013078396A2 (en) 2011-11-23 2013-05-30 Durect Corporation Radiation-sterilized biodegradable drug delivery compositions
AU2013212583A1 (en) 2012-01-23 2014-08-14 Allergan, Inc. Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
HK1220628A1 (zh) * 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
JP2016514692A (ja) 2013-03-15 2016-05-23 デュレクト コーポレーション チキソトロピーならびに強化された溶解再現性及び安定性を有する組成物
KR102245354B1 (ko) 2013-05-24 2021-04-30 아이콘 바이오사이언스, 인크. 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도
EP3220887A1 (en) 2014-11-21 2017-09-27 Technical University of Denmark Gel formulations for local drug release
WO2016148228A1 (ja) 2015-03-18 2016-09-22 参天製薬株式会社 徐放性医薬組成物
AR105215A1 (es) 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico
JP7051721B2 (ja) 2016-06-30 2022-04-11 デュレクト コーポレーション デポー製剤
JP7030813B2 (ja) 2017-01-06 2022-03-07 参天製薬株式会社 前立腺癌の処置のためのシロリムスの腫瘍内投与

Also Published As

Publication number Publication date
CN109310680B (zh) 2022-11-01
AU2023202823A1 (en) 2023-05-25
IL263714A (en) 2019-01-31
MX387477B (es) 2025-03-18
TWI765898B (zh) 2022-06-01
MX2018016424A (es) 2019-08-12
US10668011B2 (en) 2020-06-02
JP7051721B2 (ja) 2022-04-11
JP2022088568A (ja) 2022-06-14
WO2019133735A1 (en) 2019-07-04
KR20190025635A (ko) 2019-03-11
BR112018077259A2 (pt) 2019-06-18
PH12018502615A1 (en) 2019-09-30
CN115645399A (zh) 2023-01-31
UA124768C2 (uk) 2021-11-17
AU2017290143A1 (en) 2019-02-21
GEAP202014989A (en) 2020-07-27
EP3478285A1 (en) 2019-05-08
WO2018005777A1 (en) 2018-01-04
US20200352852A1 (en) 2020-11-12
EP3478285A4 (en) 2020-07-22
TW201811374A (zh) 2018-04-01
JP2019526532A (ja) 2019-09-19
US20180000729A1 (en) 2018-01-04
CN109310680A (zh) 2019-02-05
SG11201810618QA (en) 2019-01-30
CA2972296A1 (en) 2017-12-30

Similar Documents

Publication Publication Date Title
GEP20207204B (en) Depot formulations
EP3898922A4 (en) SOLVENT COMPOSITIONS CONTAINING 1,2,2-TRIFLUORO-1-TRIFLUOROMETHYLCYCLOBUTANE (TFMCB)
EA201790977A1 (ru) Способы и композиции, относящиеся к применению поверхностно-активных веществ с низким показателем гидрофильно-липофильного баланса (hlb) при получении синтетических наноносителей, включающих рапалог
WO2018109174A3 (en) Il-11 antibodies
WO2016073789A3 (en) Anti-fgfr2/3 antibodies and methods using same
WO2018006074A3 (en) Compounds and methods for modulating rna function
PH12018502670A1 (en) Stable liquid pharmaceutical preparation
WO2018109170A3 (en) Il-11ra antibodies
EP4556069A3 (en) Modulators of sestrin-gator2 interaction and uses thereof
EP4112611A3 (en) Modulators of sestrin-gator2 interaction and uses thereof
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MX2016013628A (es) Sistema de envasado.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
EP3666076A3 (en) Agricultural pesticide compositions
MX2020004424A (es) Formulacion aerosolizable.
WO2017087912A3 (en) Ratiometric biosensors and non-geometrically modulated fret
PH12017501567B1 (en) Ophthalmic composition
MY195399A (en) Mixed Decyl Mercaptans Compositions and Methods Of Making Same
EA202090732A1 (ru) Составы для трансдермального введения
MX372702B (es) Una composicion antimicrobiana.
WO2019020598A3 (en) COMPOSITION
WO2018183219A3 (en) Nucleic acid-based compositions and methods for treating small vessel diseases
MX2018003895A (es) Composiciones químicas de poliimidas siloxánicas halogenadas y artículos de vidrio con recubrimientos de baja fricción de poliimidas siloxánicas halogenadas.
WO2019103875A3 (en) Methods of using and compositions containing dulaglutide